Meeting
2017 ASCO Annual Meeting
Tivo-3: A phase 3, randomized, controlled, multi-center, open-label study to compare tivozanib hydrochloride to sorafenib in subjects with refractory advanced renal cell carcinoma (RCC).
Authors
Brian I. Rini
Cleveland Clinic Taussig Cancer Insitute, Cleveland, OH
Brian I. Rini , Michael B. Atkins , Bernard J. Escudier , Thomas E. Hutson , Piotr Koralewski , David F. McDermott , Sumanta K. Pal , Michael N. Needle , Camillo Porta
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Genitourinary (Nonprostate) Cancer
Track
Genitourinary Cancer—Kidney and Bladder
Sub Track
Kidney Cancer
Clinical Trial Registration Number
NCT02627963
Citation
J Clin Oncol 35, 2017 (suppl; abstr TPS4600)
DOI
10.1200/JCO.2017.35.15_suppl.TPS4600
Abstract #
TPS4600
Poster Bd #
273a
Abstract Disclosures
Similar Posters
Poster
2019 ASCO Annual Meeting
TIVO-3: Subgroup analysis of progression-free survival of tivozanib compared to sorafenib in subjects with refractory advanced renal cell carcinoma (RCC).
First Author: Camillo Porta
Poster
2013 Genitourinary Cancers Symposium
Overall survival results from a phase III study of tivozanib hydrochloride versus sorafenib in patients with renal cell carcinoma.
First Author: Robert John Motzer
Poster
2023 ASCO Gastrointestinal Cancers Symposium
INTEGRATE IIa: A randomised, double-blind, phase III study of regorafenib versus placebo in refractory advanced gastro-oesophageal cancer (AGOC)—A study led by the Australasian Gastro-intestinal Trials Group (AGITG).
First Author: Nick Pavlakis
Poster
2021 Genitourinary Cancers Symposium
Q-TWiST analysis of tivozanib (T) versus sorafenib (S) in patients with advanced renal cell carcinoma (RCC) in the TIVO-3 study.
First Author: Michael Szarek